Home » Stocks » OVID

Ovid Therapeutics Inc. (OVID)

Stock Price: $3.63 USD -0.15 (-3.97%)
Updated Apr 19, 2021 11:39 AM EDT - Market open
Market Cap 260.82M
Revenue (ttm) 12.62M
Net Income (ttm) -81.04M
Shares Out 58.45M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE 1.87
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $3.63
Previous Close $3.78
Change ($) -0.15
Change (%) -3.97%
Day's Open 3.66
Day's Range 3.60 - 3.84
Day's Volume 398,482
52-Week Range 2.25 - 9.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

Other stocks mentioned: AIM, ASXC, CLSN, IBIO, JAGX, RIGL, VBIV
1 month ago - InvestorPlace

Ovid Therapeutics (OVID) stock is soaring higher on Wednesday after announcing a massive deal with Takeda Pharmaceutical (TKPHF). The post OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocket...

1 month ago - InvestorPlace

Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesd...

Other stocks mentioned: KMPH, SRNE, AQST
1 month ago - Benzinga

Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic en...

Other stocks mentioned: TAK
1 month ago - Benzinga

OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda has entered into an exclusive agreement with partner Ovid Therapeutics to develop and commercialize the investigational medicine soticlestat.

Other stocks mentioned: TAK
1 month ago - Business Wire

NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

4 months ago - GlobeNewsWire

Ovid Therapeutics (OVID) news for Wednesday concerning results from a recent clinical trial have OVID stock taking a beating. The post Ovid Therapeutics News: Why OVID Stock Is Plunging 55% Today appear...

4 months ago - InvestorPlace

The company reported disappointing results from a late-stage clinical trial.

4 months ago - The Motley Fool

NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinical develop...

4 months ago - GlobeNewsWire

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

5 months ago - GlobeNewsWire

NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

6 months ago - GlobeNewsWire

NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...

6 months ago - GlobeNewsWire

NEW YORK, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologica...

6 months ago - GlobeNewsWire

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologi...

7 months ago - GlobeNewsWire

Ovid Therapeutics: Strong Buy After Fall On Necessary Dilution Backed By Positive Data

7 months ago - Seeking Alpha

NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurolog...

7 months ago - GlobeNewsWire

NEW YORK and OSAKA, Japan, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceuti...

7 months ago - GlobeNewsWire

NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

8 months ago - GlobeNewsWire

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

8 months ago - GlobeNewsWire

Ovid Therapeutics Is Quickly Approaching A Transformational Valuation Milestone

8 months ago - Seeking Alpha

Here are the best biotech stocks for investors looking for market-beating performance.

Other stocks mentioned: GBT, MESO
8 months ago - The Motley Fool

NEW YORK and FARMINGTON, Conn., July 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of peopl...

8 months ago - GlobeNewsWire

One analyst thinks the stock still has significant upside. Is that enough to justify its price?

9 months ago - The Motley Fool

NEW YORK and ROME, July 13, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID, hereinafter “Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives o...

9 months ago - GlobeNewsWire

NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

9 months ago - GlobeNewsWire

Ovid Therapeutics (OVID) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

10 months ago - GlobeNewsWire

The small-cap biopharma got a nod from an analyst.

10 months ago - The Motley Fool

When choosing cheap stocks to invest in you don't always have to sacrifice quality. Here are four high-quality companies that are affordable.

Other stocks mentioned: INVE, PLUG, VG
10 months ago - InvestorPlace

NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

10 months ago - GlobeNewsWire

For new investors, stocks under $10 offer both learning opportunities and huge upside potential. Here are 10 names to buy cheap.

Other stocks mentioned: BTG, CSTM, DVAX, INVE, LIVX, PLUG, SQNS ...
10 months ago - InvestorPlace

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

10 months ago - GlobeNewsWire

Ovid Advances Fragile X Syndrome Drug Forward; Multiple Catalysts Still Expected In 2020

11 months ago - Seeking Alpha

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologica...

11 months ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for April 22nd

Other stocks mentioned: ASC, CRMD, FUV
11 months ago - Zacks Investment Research

The coronavirus pandemic has cast the spotlight on the world of biotechnology stocks as researchers search for not only a vaccine, but for additional drugs that can help in the treatment of the virus.

Other stocks mentioned: GILD, ICPT, ITCI, KPTI
1 year ago - 24/7 Wall Street

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologi...

1 year ago - GlobeNewsWire

No matter what, investors are always after returns. These six cheap stocks can make those returns a reality in 2020.

Other stocks mentioned: CDTX, CPE, KDMN, NEX, QEP
1 year ago - InvestorPlace

Snapping up strong buy stocks with great long-term growth prospects doesn’t have to cost you your entire savings. The post 5 Strong Buy Stocks Under $5 With Massive Upside Potential appeared first on I...

Other stocks mentioned: ITI, MTNB, OGI, PLUG
1 year ago - InvestorPlace

Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team

1 year ago - GlobeNewsWire

These stocks come from a variety of industries, but all have positive catalysts in their futures. Buy these cheap stocks now while you can.

Other stocks mentioned: AMC, ANGI, GLUU, ITI, MEET, PLUG, TH ...
1 year ago - InvestorPlace

As of late, it has definitely been a great time to be an investor Ovid Therapeutics.

1 year ago - Zacks Investment Research

NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurolog...

1 year ago - GlobeNewsWire

NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurolog...

1 year ago - GlobeNewsWire

Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population

1 year ago - GlobeNewsWire

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologi...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologi...

1 year ago - GlobeNewsWire

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-lik... [Read more...]

Industry
Biotechnology
IPO Date
May 5, 2017
CEO
Jeremy Levin
Employees
67
Stock Exchange
NASDAQ
Ticker Symbol
OVID
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for OVID stock is "Buy." The 12-month stock price forecast is 6.25, which is an increase of 72.18% from the latest price.

Price Target
$6.25
(72.18% upside)
Analyst Consensus: Buy